Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification

Journal of Hematopathology

Volumn 2, Issue 4, 2009, Pages 205-210

  Hebeda, Konnie M ^a   Fend, F ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Review. classification. myelodysplastic syndrome. myeloproliferative neoplasm. updated who classification

Indexed keywords

EID: 78650810489     PISSN: None     EISSN: 18655785     Source Type: Journal    
DOI: 10.1007/s12308-009-0048-6     Document Type: Review

References (6)

1. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
2. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092-1097 Epub 2007 May 8
3. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128-1132
4. Fend F, Horn T, Koch I, Vela T, Orazi A (2008) Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res 32(12):1931-1935 Epub 2008 Jun 13
5. Wardrop D, Steensma DP (2009) Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol 144(6):809-817 Epub 2008 Dec 11
6. Ades L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C, Dreyfus F, Stamatoullas A, Chaury MP, Delaunay J, Laurent G, Vey N, Burcheri S, Mbida RM, Hoarau N, Gardin C, Fenaux P (2009) Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study. Blood 113(17):3947-3952 Epub 2008 Nov 5